Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Accumulated Expenses (2016 - 2025)

Karyopharm Therapeutics' Accumulated Expenses history spans 14 years, with the latest figure at $64.5 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 6.34% year-over-year to $64.5 million; the TTM value through Dec 2025 reached $64.5 million, up 6.34%, while the annual FY2025 figure was $64.5 million, 6.34% up from the prior year.
  • Accumulated Expenses reached $64.5 million in Q4 2025 per KPTI's latest filing, down from $66.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $69.1 million in Q4 2021 to a low of $19.6 million in Q4 2022.
  • Average Accumulated Expenses over 5 years is $55.8 million, with a median of $56.0 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: soared 326.3% in 2021, then crashed 71.61% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $69.1 million in 2021, then plummeted by 71.61% to $19.6 million in 2022, then surged by 212.84% to $61.4 million in 2023, then fell by 1.21% to $60.7 million in 2024, then increased by 6.34% to $64.5 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Accumulated Expenses are $64.5 million (Q4 2025), $66.3 million (Q3 2025), and $62.9 million (Q2 2025).